GCG and steatosis: OXM-104, along-acting oxyntomodulin analog, showed greater reductions in steatosis,fibrosis, and liver injury markers compared to semaglutide, and improved NAFLDactivity score (NAS), highlighting its potential in treating liver-relatedmetabolic complications [60].